title: Long-term treatment of central Cushing's syndrome with rosiglitazone.
abstract: BACKGROUND
  Central Cushing's syndrome is not always curable by surgery or radiation of the pituitary. Medical treatment is often not possible or effective. Some studies revealed beneficial effects of the PPARgamma (Peroxisome-Proliferator-Activator- Receptor-gamma)-agonist rosiglitazone (RG) in in vitro studies, animal models and short term clinical studies.
  
  
  OBJECTIVE
  of this study was to observe the long-term effects of RG-treatment on cortisol- and ACTH -secretion, clinical outcomes and morphological changes of the pituitary in patients with persistent ACTH-overproduction despite previous operation and radiation.
  
  
  METHODS
  14 patients with persistent central ACTH -production were included and monitored over a period up to 12 months. RG was administered daily and increased to a maximum dosage of 24 mg daily, according to the response of ACTH and cortisol secretion. ACTH and cortisol were measured at least every 4 weeks during RG treatment.
  
  
  RESULTS
  Patients were treated between 4 and 12 months with RG (mean 6.8 months). Compared to baseline, ACTH- and cortisol levels dropped significantly (p<0.01) after 12, 16, 20, 24 and 28 weeks but thereafter rose again during the study period, despite continuous RG- treatment and dose increase up to the maximum dosage. This was paralleled by reocurrence of clinical symptoms. MRI-scans were performed in 6 patients because of persisting visible adenoma, but showed no morphological changes.
  
  
  CONCLUSIONS
  RG seems not to be a long-term treatment option for patients with persistent central ACTH-evcess. Though, in order to reduce perioperative complications, short term treatment of patients could be an alternative.
authors.affiliation: University of Heidelberg, Department of Internal Medicine, Endocrinology, Metabolism and Clinical Chemistry Heidelberg, Germany. Michael_Morcos@med.uni-heidelberg.de
authors.forename: M
authors.initials: M
authors.lastname: Morcos
authors.forename: B
authors.initials: B
authors.lastname: Fohr
authors.forename: J
authors.initials: J
authors.lastname: Tafel
authors.forename: F
authors.initials: F
authors.lastname: Pfisterer
authors.forename: A
authors.initials: A
authors.lastname: Hamann
authors.forename: P
authors.initials: P
authors.lastname: Humpert
authors.forename: H
authors.initials: H
authors.lastname: Bode
authors.forename: V
authors.initials: V
authors.lastname: Schwenger
authors.forename: M
authors.initials: M
authors.lastname: Zeier
authors.forename: C
authors.initials: C
authors.lastname: Becker
authors.forename: C
authors.initials: C
authors.lastname: Kasperk
authors.forename: T
authors.initials: T
authors.lastname: Schilling
authors.forename: H P
authors.initials: HP
authors.lastname: Hammes
authors.forename: A
authors.initials: A
authors.lastname: Bierhaus
authors.forename: P P
authors.initials: PP
authors.lastname: Nawroth
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000097:blood / Q000378:metabolism; D003480:Cushing Syndrome / Q000097:blood / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D000077154:Rosiglitazone; D016879:Salvage Therapy; D045162:Thiazolidinediones / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000324:Adrenocorticotropic Hormone; D006854:Hydrocortisone